Lantern Pharma (LTRN) director reports grant of 46,152 stock options

Rhea-AI Filing Summary

Lantern Pharma Inc. director Maria-Luisa Maccecchini reported receiving two stock option grants. On January 9, 2026, she was awarded a stock option to buy 25,000 shares of common stock at an exercise price of $3.49 per share, with the option priced at $0.00 on the grant date. She also received a second stock option for 21,152 shares at the same $3.49 exercise price.

Both grants were made under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The 25,000-share option vests in equal monthly installments over 24 months starting February 9, 2026, while the 21,152-share option vests in equal monthly installments over 12 months beginning on the same date. Following these grants, she directly beneficially owns 25,000 and 21,152 derivative securities, respectively.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maccecchini Maria-Luisa

(Last) (First) (Middle)

1920 MCKINNEY AVENUE, 7TH FLOOR

(Street)

DALLAS TX 75201

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lantern Pharma Inc. [ LTRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.49	01/09/2026		A		25,000		(1)	01/08/2036	Common Stock	25,000	$0.00	25,000	D
Stock Option (Right to Buy)	$3.49	01/09/2026		A		21,152		(2)	01/08/2036	Common Stock	21,152	$0.00	21,152	D

Explanation of Responses:

1. The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026.

2. The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026.

	/s/ Maria Luisa Maccecchini	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lantern Pharma (LTRN) report on this Form 4?

The filing reports that director Maria-Luisa Maccecchini received two grants of stock options (rights to buy common stock) on January 9, 2026 under Lantern Pharma Inc.’s Amended and Restated 2018 Stock Incentive Plan.

How many stock options did Lantern Pharma director Maria-Luisa Maccecchini receive?

She received a stock option for 25,000 shares of common stock and a separate stock option for 21,152 shares of common stock, both recorded as derivative securities beneficially owned directly.

What is the exercise price of the Lantern Pharma (LTRN) stock options granted on January 9, 2026?

Both stock option grants have a conversion or exercise price of $3.49 per share, and each option was shown with a $0.00 price on the grant date, reflecting that they were awarded, not purchased for cash.

What are the vesting schedules for the Lantern Pharma stock options reported in this Form 4?

For the 25,000-share option, vesting occurs in equal monthly increments over 24 months starting February 9, 2026. For the 21,152-share option, vesting occurs in equal monthly increments over 12 months beginning on February 9, 2026.

When do the Lantern Pharma options granted to Maria-Luisa Maccecchini expire?

Both stock options carry an expiration date of January 8, 2036, as shown in the derivative securities table, giving a long-term window during which vested portions may be exercised.

Are the stock options held directly or indirectly by the reporting person in this Lantern Pharma Form 4?

The Form 4 shows the options as directly owned (coded D) by Maria-Luisa Maccecchini, with no separate nature of indirect beneficial ownership indicated.